サインイン 無料でサインアップします。

Panbela TherapeuticsのEPS Q / Q

Panbela TherapeuticsのEPS Q / Qは何ですか。

Panbela Therapeutics Inc.のEPS Q / Qは586.36%です。

EPS Q / Qの定義は何ですか。



四半期EPS成長率(Quarterly EPS growth rate)は、過去4四半期の業績と比較して過去4四半期のEPSの増加です。

The earnings per share growth rate is an important factor for judging a company's value. EPS growth rate gives a good picture of the rate at which the company has grown its profitability in respect to the total number of shares. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.

Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.

NASDAQのセクタHealth CareにおけるEPS Q / Qの企業と比べるPanbela Therapeutics

Panbela Therapeuticsは何をしますか。

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Panbela Therapeuticsと類似のeps q / q